Human leukocyte antigen class i alleles and the risk of chronic myelogenous leukemia: A meta-analysis

Leukemia and Lymphoma

Volumn 51, Issue 7, 2010, Pages 1288-1292

  Naugler, Christopher ^a   Liwski, Robert ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Chronic myelogenous leukemia; HLA allele; meta analysis

Indexed keywords

BCR ABL PROTEIN; HLA A1 ANTIGEN; HLA A11 ANTIGEN; HLA A2 ANTIGEN; HLA A24 ANTIGEN; HLA A26 ANTIGEN; HLA A29 ANTIGEN; HLA A3 ANTIGEN; HLA A30 ANTIGEN; HLA A31 ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; HLA B13 ANTIGEN; HLA B15 ANTIGEN; HLA B18 ANTIGEN; HLA B27 ANTIGEN; HLA B35 ANTIGEN; HLA B37 ANTIGEN; HLA B38 ANTIGEN; HLA B40 ANTIGEN; HLA B44 ANTIGEN; HLA B49 ANTIGEN; HLA B50 ANTIGEN; HLA B51 ANTIGEN; HLA B52 ANTIGEN; HLA B55 ANTIGEN; HLA B57 ANTIGEN; HLA B58 ANTIGEN; HLA B7 ANTIGEN; HLA B8 ANTIGEN; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CANADA; CANCER RISK; CHINA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; EPIDEMIOLOGICAL DATA; EUROPE; FINLAND; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; IMMUNE RESPONSE; INDIA; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC REVIEW; TURKEY (REPUBLIC);

ALLELES; HLA-A ANTIGENS; HLA-B ANTIGENS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; POLYMORPHISM, GENETIC; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 77954114684     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428191003802340     Document Type: Article

References (29)

1. Naugler C, Liwski R. HLA risk markers for chronic myelogenous leukemia in Eastern Canada. Leuk Lymphoma 2009;50:254-259.
2. Pinilla-Ibarz J, Cathcart K, Scheinberg DA. CML vaccines as a paradigm of the specific immunotherapy of cancer. Blood Rev 2000;14:111-120.
3. Schmitt M, Li L, Giannopoulos K, et al. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+T-cell responses and are lacking costimulatory molecules. Exp Hematol 2006;34:1709-1719.
4. Oguz FS, Kalayoglu S, Diler AS, et al. HLA system affects the age-at-onset in chronic myeloid leukemia. Am J Hematol 2003;73:256-262.
5. Dorak MT, Chalmers EA, Gaffney D, et al. Human major histocompatibility complex contains several leukemia susceptibility genes. Leuk Lymphoma 1994;12:211-222.
6. Liu J-B, Li M, Chen H, et al. Association of vitiligo with HLAA2: a meta analysis. J Eur Acad Dermatol Venereol 2006; 2:205-213.
7. Delgato-Vega AM, Anaya JM. Meta-analysis of HLA-DRB1 polymorphism in Latin American patients with rheumatoid arthritis. Autoimmun Rev 2007;6:402-408.
8. Stokkers PCF, Reitsma PH, Tygat GNJ, et al. HLA-DR and - DQ phenotypes in inflammatory bowel disease: a meta analysis. Gut 1999;45:395-401.
9. Chhaya SU. Human leukocyte antigens in Indian patients with chronic myeloid leukemia. Leuk Lymphoma 2006;47:291-295.
10. Miao KR, Pan QQ, Xue M, et al. Human leukocyte antigens in 295 Chinese patients with chronic myeloid leukemia. Leuk Lymphoma 2007;48:2152-2156.
11. Wei L, Xiao LL, Wu XY, et al. [Expression and analysis of HLA-A, B and DRB1 genes in patients with chronic myelogenous leukemia in Guangdong area]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008;16:915-918.
12. Li D, Xi B, Liu HY, Yu Y. [Association of gene HLA-class I with leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2005;13:563-566.
13. Posthuma EF, Falkenburg JH, Apperley JF, et al. HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT. Blood 1999;93:3863-3865.
14. Ruuska P, Silvennoinen-Kassinen S, Timonen T, Tiilikainen A. Chronic myelocytic leukaemia: HLA association and decreased erythrocyte C3b receptor expression. Clin Exp Immunol 1985;59:300-304.
15. Review Manager (RevMan) version 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2003.
16. Bocchia M, Wentworth PA, Southwood S, et al. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 1995;85:2680-2684.
17. Greco G, Fruci D, Accapezzato D, et al. Two brc-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Leukemia 1996;10:693-699.
18. Buzyn A, Ostankovitch M, Zerbib A, et al. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes. Eur J Immunol 1997;27:2066-2072.
19. Barrett J, Guimaraes A, Cullis J, Goldman JM. Immunological characterization of the tumor-specific bcr/abl junction of Philadelphia chromosome positive chronic myeloid leukemia. Stem Cells 1993;11:104-108.
20. Cullis JO, Barrett AJ, Goldman JM, Lechler RI. Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I molecules: studies in antigenprocessing defective cell lines. Leukemia 1994;8:165-170.
21. Kessler JH, Bres-Vloemans SA, van Veelen PA, et al. BCRABL fusion regions as a source of multiple leukemia-specific CD8+T cell epitopes. Leukemia 2006;20:1738-1750.
22. Rezvani K, Grube M, Brenchley JM, et al. Functional leukemia-associated antigen-specific memory CD8+T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 2003;102:2892-2900.
23. Cathcart K, Pinilla-Ibarz J, Korontsvit T, et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004;103:1037-1042.
24. Yotnda P, Firat H, Garcia-Pons F, et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 1998;101:2290-2296. (Pubitemid 28244113)
25. Molldrem JJ, Lee PP, Kant S, et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of highavidity leukemia-specific T cells. J Clin Invest 2003;111:639-647.
26. Molldrem JJ. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000;6:1018-1023.
27. Bellantuono I, Gao L, Parry S, et al. Two distinct HLAA0201- presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood 2002;100:3835-3837.
28. Gannage M, Abel M, Michallet AS, et al. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J Immunol 2005;174:8210-8218.
29. Maslak PG, Dao T, Gomez M, et al. A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease. Leukemia 2008;22:1613-1616.